Cancer-Killing virus plus immunotherapy shows promise in tough breast cancers
NCT ID NCT03802604
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early study tested a combination of a modified herpes virus (T-VEC) and an immunotherapy drug (atezolizumab) in 28 women with aggressive breast cancer that did not fully disappear after standard chemotherapy. The virus was injected directly into tumors to kill cancer cells and spark an immune response, while the drug helped the immune system attack more effectively. The goal was to see if this combo could further reduce or eliminate remaining cancer before surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Talimogene laherparepvec (a modified herpes virus) and atezolizumab (an immunotherapy drug)
What this could lead to
If it works, this combination could help shrink or eliminate remaining breast cancer after standard chemotherapy, potentially reducing the risk of recurrence.
What could go wrong
This is a very early, small study (28 participants) with no control group, so results are preliminary. The virus injection and immunotherapy can cause side effects like flu-like symptoms or immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro Integral Oncológico Clara Campal
Madrid, Madrid, 28050, Spain
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
-
Hospital Clínico universitario de Valencia
Valencia, Valencia, 46010, Spain
-
Hospital Universitari Vall d'Hebrón
Barcelona, Barcelona, 08035, Spain